Zeo ScientifiX, Inc.
Close on Oct 19, 2026
- Market cap
- $7.08M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Apr 30, 2026 | Jul 8, 2026 | Before market open | $2.58M | – | – |
Press releases
Announcements Zeo ScientifiX filed with the SEC
ZEO ScientifiX Plans Expansion into Georgia and Tennessee as New Regenerative Medicine Laws Take Effect
Other events · EX-99.1 to Form 8-K
ZEO ScientifiX Announces Multidisciplinary Expert Faculty Lineup for the ZEO Xperience
Other events · EX-99.1 to Form 8-K
ZEO ScientifiX Launches First-of-Its-Kind ZEO
Other events · EX-99.1 to Form 8-K
ZEO ScientifiX Strengthens South Florida’s Growing Biotechnology Ecosystem Through Regenerative Medicine Innovation
Other events · EX-99.1 to Form 8-K
ZEO ScientifiX Reports Strong Revenue Growth Of For Three Months and Six Months Ended April 30, 2026
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
ZEO ScientifiX to Host Live Educational Webinar
Other events · EX-99.1 to Form 8-K
ZEO ScientifiX Donates Products to Support Pediatric Burn Reconstruction Mission in Peru
Other events · EX-99.1 to Form 8-K
ZEO ScientifiX Expands Medical Advisory Board with Leaders in Regenerative and Longevity Medicine
Other events · EX-99.1 to Form 8-K
ScientifiX Launches Physician-Led Patient Masterclass Program
Other events · EX-99.1 to Form 8-K
ZEO ScientifiX Announces That Unaudited Monthly
Other events · EX-99.1 to Form 8-K
ZEO ScientifiX Surpasses 500 Physicians Trained in Regenerative Medicine Compliance; Monthly Masterclasses Average 70+ Clinicians
Other events · EX-99.1 to Form 8-K
Therapy Partners with Stealth Health to Bring Specialized
Other events · EX-99.1 to Form 8-K
ZEO ScientifiX (OTCQB: ZEOX) Selected as Qualified Team Advancing into the XPRIZE Healthspan Semi-Finals Stage
Other events · EX-99.1 to Form 8-K
ZEO ScientifiX Solidifies Role as Official
Other events · EX-99.1 to Form 8-K
ZEO ScientifiX™ Positioned for New Growth as Florida Opens Stem Cell Market
Other events · EX-99.1 to Form 8-K
ZEO ScientifiX Positions for National Growth
Other events · EX-99.1 to Form 8-K
ZEO ScientifiX Launches Physician-Focused Masterclass Ahead of Florida’s SB-1768 Law Implementation
Other events · EX-99.1 to Form 8-K
ZEO ScientifiX Strengthens Leadership Team With The Appointment of Dr. Peter
Other events · EX-99.1 to Form 8-K
ZEO ScientifiX Provides Business Update to Stockholders and the Investment Community
Other events · EX-99.1 to Form 8-K
Private and Confidential. © 2024 ZEO ScientifiX , Inc. All rights reserved.
Regulation FD disclosure · EX-99.1 to Form 8-K/A
P r i v a te a n d Co nfide n tial. © 2 024 Z EO S c i e n tifi X , I n c . All r i gh t s r eserv ed.
Regulation FD disclosure · EX-99.1 to Form 8-K
SCIENTIFIX AND EXOTROPIN join forces TO LAUNCH a solution to
Other events · EX-99.1 to Form 8-K
ZEO SCIENTIFIX, A LEADING SOUTH FLORIDA BIOTECHNOLOGY COMPANY, Launches
Other events · EX-99.1 to Form 8-K
REGENERATIVE MEDICINE REBRANDING TO ZEO SCIENTIFIX
Other events · EX-99.1 to Form 8-K
Lauderdale, Florida – November 27, 2023 – Organicell Regenerative Medicine Inc, (OTCQB: OCEL) (“Organicell” or
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Organicell Reports Interim Results of Phase
Regulation FD disclosure · EX-99.1 to Form 8-K
Welcomes Howard Golub, MD, PhD as its New EVP/CSO
Regulation FD disclosure · EX-99.1 to Form 8-K
Welcomes Harry Leider, MD, MBA as its New CEO
Regulation FD disclosure · EX-99.1 to Form 8-K
Private And Confidential. © 2023 Organicell Regenerative Medicine, Inc. All rights reserved. Investor Presentation June 2023 1
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Organicell Regenerative Medicine, Inc. Responds
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K/A
Regulation FD disclosure · EX-99.1 to Form 8-K/A
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Regenerative Medicine, Inc. Announces Expansion into Health and Beauty Market
Other events · EX-99.1 to Form 8-K
Regenerative Medicine, Inc. Secures Additional $11 Million in Financing in Preparation for Clinical Trial Enrollment
Unregistered share sale · Executive or director change · Other events · EX-99.1 to Form 8-K
Medicine, Inc. Engages law firm McDermott Will & Emery
Other events · EX-99.1 to Form 8-K
Regenerative Medicine, Inc. Closes $5.5 Million Funding Round
Other events · EX-99.1 to Form 8-K
REGENERATIVE MEDICINE, INC. SECURES $4 MILLION IN FUNDING FOR CLINICAL TRIALS AND AGREES TO RESTRUCTURE MANAGEMENT
Other events · EX-99.1 to Form 8-K
And Proxima CRO Set To Open Clinical Trial For Long Hauler COVID-19 Patients
Other events · EX-99.1 to Form 8-K
REGENERATIVE MEDICINE, INC. PROVIDES UPDATES OF CLINICAL TRIAL ACTIVITIES
Other events · EX-99.1 to Form 8-K